Wuhan Hiteck Biological Pharma Co Ltd
SZSE:300683
Wuhan Hiteck Biological Pharma Co Ltd
SZSE:300683
Price:
31.96
CNY
-2.29%
Market Closed
Market Cap:
¥4.2B
Balance Sheet
Balance Sheet Decomposition
Wuhan Hiteck Biological Pharma Co Ltd
Wuhan Hiteck Biological Pharma Co Ltd
Balance Sheet Decomposition is not available for
Wuhan Hiteck Biological Pharma Co Ltd
Wuhan Hiteck Biological Pharma Co Ltd
Balance Sheet
Wuhan Hiteck Biological Pharma Co Ltd
Wuhan Hiteck Biological Pharma Co Ltd
Currency: CNY
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & Cash Equivalents |
472
|
496
|
608
|
698
|
307
|
696
|
461
|
182
|
748
|
510
|
419
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
182
|
748
|
510
|
419
|
|
| Cash Equivalents |
472
|
496
|
608
|
698
|
307
|
695
|
461
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
480
|
539
|
1 006
|
287
|
579
|
454
|
|
| Total Receivables |
212
|
195
|
269
|
274
|
241
|
221
|
248
|
298
|
264
|
270
|
317
|
|
| Accounts Receivables |
195
|
174
|
218
|
234
|
216
|
203
|
221
|
240
|
218
|
231
|
282
|
|
| Other Receivables |
17
|
21
|
51
|
40
|
25
|
18
|
27
|
59
|
46
|
39
|
35
|
|
| Inventory |
25
|
22
|
15
|
22
|
35
|
57
|
70
|
72
|
120
|
117
|
109
|
|
| Other Current Assets |
5
|
41
|
5
|
755
|
963
|
16
|
11
|
24
|
25
|
11
|
7
|
|
| Total Current Assets |
714
|
755
|
896
|
1 749
|
1 546
|
1 469
|
1 328
|
1 583
|
1 444
|
1 488
|
1 306
|
|
| PP&E Net |
61
|
80
|
103
|
112
|
226
|
316
|
376
|
564
|
695
|
754
|
732
|
|
| PP&E Gross |
61
|
80
|
103
|
112
|
226
|
316
|
376
|
564
|
695
|
754
|
732
|
|
| Accumulated Depreciation |
43
|
49
|
55
|
63
|
98
|
117
|
134
|
165
|
212
|
275
|
334
|
|
| Intangible Assets |
20
|
20
|
19
|
18
|
66
|
64
|
95
|
90
|
91
|
299
|
279
|
|
| Goodwill |
0
|
0
|
0
|
0
|
275
|
276
|
316
|
316
|
302
|
264
|
264
|
|
| Long-Term Investments |
3
|
3
|
3
|
7
|
9
|
7
|
8
|
68
|
89
|
47
|
227
|
|
| Other Long-Term Assets |
3
|
15
|
19
|
23
|
33
|
39
|
63
|
76
|
84
|
120
|
129
|
|
| Other Assets |
0
|
0
|
0
|
0
|
275
|
276
|
316
|
316
|
302
|
264
|
264
|
|
| Total Assets |
801
N/A
|
873
+9%
|
1 039
+19%
|
1 909
+84%
|
2 155
+13%
|
2 170
+1%
|
2 187
+1%
|
2 698
+23%
|
2 706
+0%
|
2 971
+10%
|
2 937
-1%
|
|
| Liabilities | ||||||||||||
| Accounts Payable |
8
|
6
|
7
|
8
|
14
|
28
|
51
|
48
|
58
|
52
|
64
|
|
| Accrued Liabilities |
5
|
9
|
10
|
12
|
23
|
26
|
29
|
35
|
40
|
48
|
48
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
18
|
7
|
37
|
30
|
10
|
8
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
205
|
0
|
0
|
5
|
29
|
22
|
23
|
|
| Other Current Liabilities |
249
|
254
|
309
|
236
|
189
|
314
|
281
|
124
|
128
|
215
|
220
|
|
| Total Current Liabilities |
262
|
270
|
326
|
256
|
431
|
386
|
367
|
249
|
285
|
346
|
363
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
52
|
46
|
83
|
63
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
6
|
6
|
8
|
7
|
13
|
16
|
15
|
|
| Minority Interest |
2
|
1
|
7
|
7
|
10
|
8
|
16
|
19
|
25
|
17
|
20
|
|
| Other Liabilities |
3
|
6
|
10
|
10
|
9
|
18
|
86
|
46
|
28
|
30
|
84
|
|
| Total Liabilities |
267
N/A
|
277
+4%
|
342
+24%
|
272
-20%
|
456
+67%
|
417
-8%
|
478
+15%
|
373
-22%
|
396
+6%
|
493
+25%
|
545
+10%
|
|
| Equity | ||||||||||||
| Common Stock |
76
|
78
|
78
|
103
|
103
|
103
|
103
|
122
|
122
|
131
|
131
|
|
| Retained Earnings |
268
|
302
|
401
|
544
|
607
|
659
|
618
|
645
|
631
|
510
|
424
|
|
| Additional Paid In Capital |
191
|
216
|
218
|
990
|
990
|
990
|
988
|
1 557
|
1 557
|
1 837
|
1 837
|
|
| Total Equity |
535
N/A
|
596
+11%
|
697
+17%
|
1 636
+135%
|
1 700
+4%
|
1 752
+3%
|
1 709
-2%
|
2 324
+36%
|
2 310
-1%
|
2 478
+7%
|
2 392
-3%
|
|
| Total Liabilities & Equity |
801
N/A
|
873
+9%
|
1 039
+19%
|
1 909
+84%
|
2 155
+13%
|
2 170
+1%
|
2 187
+1%
|
2 698
+23%
|
2 706
+0%
|
2 971
+10%
|
2 937
-1%
|
|
| Shares Outstanding | ||||||||||||
| Common Shares Outstanding |
76
|
78
|
78
|
103
|
103
|
103
|
103
|
122
|
122
|
131
|
131
|
|
Switch to:
Switch to:
See Also
Discover More
